title: Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis.
abstract: BACKGROUND
  Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
  
  
  METHODS
  A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
  
  
  RESULTS
  CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20-0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50-4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34-0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31-0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05-2.21, P=0.027).
  
  
  CONCLUSIONS
  CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.
authors.affiliation: Department of Orthopedics, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Yaosheng
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Pulmonary Neoplasms Internal Medicine, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Haifeng
authors.initials: H
authors.lastname: Qing
authors.affiliation: Department of Orthopedics, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Xiuyun
authors.initials: X
authors.lastname: Su
authors.affiliation: Department of Orthopedics, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Cheng
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Tissue Specimen Database, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Zhou
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Orthopedics, The PLA 307th Hospital, Beijing, China (mainland).
authors.forename: Shubin
authors.initials: S
authors.lastname: Liu
mesh_terms: D000368:Aged; D000483:Alleles; D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D005838:Genotype; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics*; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: C497483:CD44 protein, human; D018960:Hyaluronan Receptors